BIBAS REDDY
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology FORT WORTH, TX NPI 1457577017
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX GlaxoSmithKline, LLC. All categories
General Payments — all program years on this page
$14,096.73
- Category: General Payments
- Program years: PY2018–2024
- Record count: 160
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,852.97 across 58 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,852.97 | 58 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $194.32 | 5 |
| Tempus AI, Inc | $159.03 | 6 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $129.04 | 5 |
| Melinta Therapeutics, Inc. | $123.94 | 1 |
| Celgene Corporation | $122.37 | 5 |
| Blueprint Medicines Corporation | $118.68 | 1 |
| E.R. Squibb & Sons, L.L.C. | $108.02 | 1 |
| Regeneron Pharmaceuticals, Inc. | $103.65 | 1 |
| Acerta Pharma LLC | $101.65 | 4 |
| Merck Sharp & Dohme Corporation | $77.15 | 3 |
| Regeneron Healthcare Solutions, Inc. | $67.61 | 2 |
| Janssen Biotech, Inc. | $56.73 | 4 |
| Daiichi Sankyo Inc. | $52.68 | 2 |
| Kite Pharma, Inc. | $49.51 | 2 |
| EISAI INC. | $49.05 | 2 |
| ARRAY BIOPHARMA INC | $48.66 | 2 |
| Astellas Pharma US Inc | $41.51 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $40.94 | 1 |
| Gilead Sciences, Inc. | $35.85 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.37 | 1 |
| Karyopharm Therapeutics Inc. | $27.28 | 1 |
| Ipsen Biopharmaceuticals, Inc | $24.57 | 1 |
| Genmab U.S., Inc. | $23.12 | 1 |
| PFIZER INC. | $22.01 | 1 |
| Stemline Therapeutics Inc. | $21.72 | 1 |
| ABBVIE INC. | $20.51 | 1 |
By program year
Records — PY2024 (58)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.